Cargando…
To be, or not to be: the dilemma of immunotherapy for non-small cell lung cancer harboring various driver mutations
INTRODUCTION: Lung cancer is one of primary cancer type with high incidence and mortality, non-small cell lung cancer (NSCLC) is the most common type of lung cncer. For advanced lung cancer, traditional chemotherapy and targeted therapy become difficult to solve the dilemma of further progress. In r...
Autores principales: | Cai, Ruoxue, Zhu, Hongyu, Liu, Ying, Sha, Huanhuan, Peng, Weiwei, Yin, Rong, Zhou, Guoren, Fang, Ying |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10423141/ https://www.ncbi.nlm.nih.gov/pubmed/37261523 http://dx.doi.org/10.1007/s00432-023-04919-4 |
Ejemplares similares
-
A case report: A new promising treatment for pulmonary sarcomatoid carcinoma - Tislelizumab and Anlotinib combined with local radiotherapy
por: Cai, Ruoxue, et al.
Publicado: (2023) -
Sporadic multiple meningiomas harbor distinct driver mutations
por: Juratli, Tareq A., et al.
Publicado: (2021) -
三级淋巴结构在非小细胞肺癌预后及免疫治疗中的研究进展
por: LIU, Ying, et al.
Publicado: (2023) -
Epithelial Cells of Deep Infiltrating Endometriosis Harbor Mutations in Cancer Driver Genes
por: Koppolu, Agnieszka, et al.
Publicado: (2021) -
Various impacts of driver mutations on the PD-L1 expression of NSCLC
por: Chu, Cheng-Hsiang, et al.
Publicado: (2022)